SCHEMBL4258782

SCHEMBL4258782

CC(C)C(=O)N1CC[C@@H](O)[C@@H]1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.41
ACE P12821 6/20 0.36
REN P00797 4/20 0.36
KDM4E B2RXH2 1/20 0.36
F2 P00734 1/20 0.36
LMNA P02545 1/20 0.36
LTA4H P09960 1/20 0.36
MAPT P10636 1/20 0.36
PEPD P12955 1/20 0.36
ALOX15 P16050 1/20 0.36
PTGS1 P23219 1/20 0.36
HTR2A P28223 1/20 0.36
PTGS2 P35354 1/20 0.36
HRH1 P35367 1/20 0.36
THPO P40225 1/20 0.36
PMP22 Q01453 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4251895 1.00 PIK3CD (0.41) PIK3CDACERENKDM4EF2
SCHEMBL4250867 1.00 PIK3CD (0.41) PIK3CDACERENKDM4EF2
SCHEMBL4254324 1.00 PIK3CD (0.41) PIK3CDACERENKDM4EF2
SCHEMBL4254321 1.00 PIK3CD (0.41) PIK3CDACERENKDM4EF2
SCHEMBL4250866 1.00 PIK3CD (0.41) PIK3CDACERENKDM4EF2
SCHEMBL11563195 0.87 ACE (0.35) ACERENKDM4EF2LMNA
SCHEMBL15756821 0.85 DPP4 (0.46) ACEDPP4
SCHEMBL19083748 0.83 PIK3CD (0.40) PIK3CDACERENKDM4EF2
SCHEMBL11046748 0.81 ACE (0.37) PIK3CDACERENKDM4EF2
SCHEMBL3235500 0.81 ACE (0.37) PIK3CDACERENKDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111632095-A Antibacterial vagina tightening and contracting composition and application thereof 上海赫依美容美体有限公司 2020-09-08 CN disclosed
US-8338404-B2 Composition and method for reducing allergen KYOWA HAKKO BIO CO., LTD. (JP) 2012-12-25 US disclosed
US-20090069403-A1 COMPOSITION AND METHOD FOR REDUCING ALLERGEN KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-03-12 US disclosed
US-20080188546-A1 Preventive or therapeutic agents for decubitus TAKEDA TOSHIAKI 2008-08-07 US disclosed
US-20080102042-A1 Dentifrices containing N-acyl derivative of hydroxyproline; periodontal disease KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-05-01 US disclosed
US-20070293559-A1 Orally Administered Agent For Preventing Or Improving Dry Station Of Skin KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-20 US disclosed
CN-101027050-A Oral preparation for preventing or improving dry skin KYOWA HAKKO KOGYO KK (JP) 2007-08-29 CN disclosed
EP-1795191-A1 ORAL PHARMACEUTICAL FOR DRY SKIN PREVENTION OR REMEDY KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-06-13 EP disclosed
US-20060034781-A1 PERORAL PREPARATION FOR PREVENTION OR TREATMENT OF ATOPIC DERMATATIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-16 US disclosed
US-20060035957-A1 Preventive or remedy for bedsore KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-02-16 US disclosed
CN-1708300-A Oral preparation for preventing or treating atopic dermatitis KYOWA HAKKO KOGYO KK (JP) 2005-12-14 CN disclosed
EP-1559425-A1 PERORAL PREPARATION FOR PREVENTION OF OR TREATMENT FOR ATOPIC DERMATITIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-08-03 EP disclosed
EP-1547594-A1 PREVENTIVE OR REMEDY FOR BEDSORE KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-06-29 EP disclosed
US-20030185864-A1 Preventives or remedies for atopic dermatitis KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-02 US disclosed
EP-1304323-A1 PREVENTIVES OR REMEDIES FOR ATOPIC DERMATITIS KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069403-A1 COMPOSITION AND METHOD FOR REDUCING ALLERGEN TSLP, CARM1, CMA1 PIK3CD 4375/4885ACE 103/4885REN 885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.